» Articles » PMID: 11863209

Quality of Life in Acute Exacerbation of Chronic Bronchitis: Results from a German Population Study

Overview
Journal Respir Med
Publisher Elsevier
Specialty Pulmonary Medicine
Date 2002 Feb 28
PMID 11863209
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

This study reports on data from a study conducted in the Federal Republic of Germany examining the quality of life (QoL) of patients with chronic bronchitis (CB) and its acute exacerbations (AECB). Data from 320 patients were collected at AECB and subsequently during a stable phase (non-AECB) utilizing the St George's Respiratory Questionnaire (SGRQ) and the Nottingham Health Profile (NHP). As expected, the QoL of CB patients was poor, even at non-AECB, with patients reporting lower scores than patients with other chronic conditions. Patients reported significantly poorer QoL at AECB than at non-AECB. After adjusting for the severity of the underlying condition, poorer QoL at AECB was significantly and independently associated with older age, unemployment, increasing BMI, increasing number of prior AECBs, and Anthonisen AECB grade. While younger subjects reported significantly greater deterioration in QoL at AECB, the factors most consistently and independently associated with relative QoL deterioration at AECB were the number of prior AECBs and exposure to air pollution at home. In conclusion, this study highlights the detrimental effect of CB, and in particular AECB, on QoL. The association between QoL and patient reports of previous AECB number and air pollution are consistent with reports from other studies.

Citing Articles

Prulifloxacin Effectiveness in Moderate-to-Severe Acute Exacerbations of Chronic Bronchitis: Α Noninterventional, Multicentre, Prospective Study in Real-Life Clinical Practice-The "AIOLOS" Study.

Gourgoulianis K, Ruggieri A, Vecchio A, Calisti F, Comandini A, Esposito G Can Respir J. 2021; 2021:6620585.

PMID: 34122678 PMC: 8172323. DOI: 10.1155/2021/6620585.


Correlation of PROMIS scales and clinical measures among chronic obstructive pulmonary disease patients with and without exacerbations.

Irwin D, Atwood Jr C, Hays R, Spritzer K, Liu H, Donohue J Qual Life Res. 2014; 24(4):999-1009.

PMID: 25307510 PMC: 4369165. DOI: 10.1007/s11136-014-0818-1.


Day-to-day measurement of patient-reported outcomes in exacerbations of chronic obstructive pulmonary disease.

Kocks J, van den Berg J, Kerstjens H, Uil S, Vonk J, de Jong Y Int J Chron Obstruct Pulmon Dis. 2013; 8:273-86.

PMID: 23766644 PMC: 3678711. DOI: 10.2147/COPD.S43992.


Efficacy and tolerability of moxifloxacin in 2338 patients with acute exacerbation of chronic bronchitis.

Barth J, Landen H Clin Drug Investig. 2013; 23(1):1-10.

PMID: 23319088 DOI: 10.2165/00044011-200323010-00001.


Relationship between frequency, length, and treatment outcome of exacerbations to baseline lung function and lung density in alpha-1 antitrypsin-deficient COPD.

Vijayasaratha K, Stockley R Int J Chron Obstruct Pulmon Dis. 2012; 7:789-96.

PMID: 23226015 PMC: 3514009. DOI: 10.2147/COPD.S31797.